SG11202008346PA - Nanoparticle compositions - Google Patents

Nanoparticle compositions

Info

Publication number
SG11202008346PA
SG11202008346PA SG11202008346PA SG11202008346PA SG11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA SG 11202008346P A SG11202008346P A SG 11202008346PA
Authority
SG
Singapore
Prior art keywords
nanoparticle compositions
nanoparticle
compositions
Prior art date
Application number
SG11202008346PA
Inventor
Raj Raheja
Robin M Jackman
Jason A Kahana
Original Assignee
January Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by January Therapeutics Inc filed Critical January Therapeutics Inc
Publication of SG11202008346PA publication Critical patent/SG11202008346PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SG11202008346PA 2018-03-02 2019-03-01 Nanoparticle compositions SG11202008346PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637965P 2018-03-02 2018-03-02
US201962798859P 2019-01-30 2019-01-30
PCT/US2019/020389 WO2019169323A1 (en) 2018-03-02 2019-03-01 Nanoparticle compositions

Publications (1)

Publication Number Publication Date
SG11202008346PA true SG11202008346PA (en) 2020-09-29

Family

ID=67805547

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008346PA SG11202008346PA (en) 2018-03-02 2019-03-01 Nanoparticle compositions

Country Status (10)

Country Link
US (1) US20210038628A1 (en)
EP (1) EP3758495A4 (en)
JP (1) JP2021516227A (en)
KR (1) KR20200143365A (en)
CN (1) CN112218533A (en)
AU (1) AU2019227986A1 (en)
CA (1) CA3092834A1 (en)
IL (1) IL277017A (en)
SG (1) SG11202008346PA (en)
WO (1) WO2019169323A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019027905A1 (en) 2017-07-31 2019-02-07 January Therapeutics, Inc. Organophosphate derivatives
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN113939526A (en) * 2019-04-22 2022-01-14 配体药物公司 Cyclic phosphate ester compound
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
JP2023523415A (en) 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド Nucleotide prodrug compounds
CN111544380B (en) * 2020-05-12 2021-03-16 武汉大学 Application of plasma replacement-free liquid composition in preparation of multiple myeloma M protein removing medicine
US11773122B2 (en) 2020-08-24 2023-10-03 Gilead Sciences. Inc. Phospholipid compounds and uses thereof
TWI811812B (en) 2020-10-16 2023-08-11 美商基利科學股份有限公司 Phospholipid compounds and uses thereof
JP2023546565A (en) * 2020-10-21 2023-11-06 リガンド・ファーマシューティカルズ・インコーポレイテッド antiviral prodrug compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874016B1 (en) * 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse NANOPARTICLES OF DERIVATIVES OF GEMCITABINE
US20130131008A1 (en) * 2011-10-25 2013-05-23 Board Of Regents, The University Of Texas System Lipophilic monophosphorylated derivatives and nanoparticles
AU2015280248B2 (en) * 2014-06-24 2021-04-08 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TWI678373B (en) * 2014-10-31 2019-12-01 日商富士軟片股份有限公司 Thionucleoside derivative or its salt and pharmaceutical composition
EP3303359A1 (en) * 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
CN104961786B (en) * 2015-06-05 2018-09-25 苏州大学 Pro-drug based on gemcitabine structure and its application
WO2019027905A1 (en) * 2017-07-31 2019-02-07 January Therapeutics, Inc. Organophosphate derivatives
CN112638927A (en) * 2018-08-20 2021-04-09 治愈生物医药公司 Gemcitabine prodrugs

Also Published As

Publication number Publication date
WO2019169323A1 (en) 2019-09-06
KR20200143365A (en) 2020-12-23
CA3092834A1 (en) 2019-09-06
EP3758495A4 (en) 2021-12-01
CN112218533A (en) 2021-01-12
AU2019227986A1 (en) 2020-10-08
JP2021516227A (en) 2021-07-01
US20210038628A1 (en) 2021-02-11
EP3758495A1 (en) 2021-01-06
IL277017A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
DK3665237T3 (en) Compositions
GB201811312D0 (en) Compositions
GB2586745B (en) Compositions
IL261792B (en) Compositions
IL260933A (en) Plinabulin compositions
IL277017A (en) Nanoparticle compositions
GB201610156D0 (en) Cliptac compositions
SG11202009259VA (en) Compositions
GB201719480D0 (en) Compositions
SG11202104306XA (en) Compositions
GB201707909D0 (en) Compositions
EP3758490A4 (en) Nanoparticle compositions
GB201803923D0 (en) Compositions
GB201707454D0 (en) Compositions
GB201614799D0 (en) Compositions
PL3609464T3 (en) Xanthohumol-based compositions
GB201622161D0 (en) Compositions
IL269120A (en) Compositions comprising avelumab
GB2570649B (en) Compositions
GB201805676D0 (en) Compositions
GB201717712D0 (en) Compositions
GB201603721D0 (en) Dental compositions
GB201602658D0 (en) Compositions
ZA202005658B (en) Compositions
PT3768284T (en) Compositions